Rheumatoid Arthritis Testing Market Size, Share & Industry Analysis, By Test Type (Serological Tests, Rheumatoid Arthritis Severity Tests & Medication Monitoring Tests, Imaging Tests), By End User (Hospitals & Clinics, Diagnostic Centers, Others) and Regional Forecast, 2024-2032

Rheumatoid arthritis is a chronic autoimmune disease, which causes inflammation in the joints, connective tissue, muscles, tendons, and fibrous tissue leading to swelling and pain. Rheumatoid arthritis usually affects the hands, wrists, and feet. In rheumatoid arthritis, the body recognizes the body tissue as antigens and starts producing antibodies against its body tissue leading to inflammation. Rheumatoid arthritis is more prevalent in women in comparison to men.

While the newer treatment options for arthritis have dramatically improved patient outcomes, severe rheumatoid arthritis can still cause physical disabilities. Notably, the latest product launches in diagnostics leading to early diagnosis have also aided the expansion of rheumatoid arthritis testing industry. For instance, in 2019, Microdrop LLC (aware), announced the launch of their at-home rheumatoid arthritis screening test, which is likely to strengthen the company’s position in rheumatoid arthritis treatment.

Key Market Driver -

Increasing prevalence of rheumatoid arthritis combined with increase in technological advancements and efficiency in testing

Key Market Restraint -

Risks associated with rheumatoid arthritis testing combined with non-reliance of some testing measures

Global rheumatoid arthritis testing market growth is being driven by the increasing prevalence of rheumatoid arthritis, increasing awareness, increasing efficient treatment options, and favorable health reimbursement. According to the World Health Organization (WHO), the global prevalence varies between 0.3% and 1.0% and is estimated to be more common in women and the developed regions. This, combined with the increasing technological advancements in rheumatoid arthritis is further expected to result in rheumatoid arthritis testing market growth.

On the flip side, the complications associated with the rheumatoid arthritis testing, the large numbers of undiagnosed rheumatoid arthritis patients and the non-reliance of some rheumatoid arthritis testing measures are the factors that can restrain the growth in global rheumatoid arthritis testing market.

Key Players Covered

The major companies covered in the global rheumatoid arthritis testing market report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Siemens Healthcare GmbH, Microdrop LLC (imaware), Augurex Life Sciences Corp., Qiagen, Svar Life Science AB (Euro Diagnostica), Exagen Inc., Aviva Systems Biology Corporation, Bio-Rad Laboratories Inc., and other players.

As per the current rheumatoid arthritis testing market trends, serological tests among the test type are anticipated to register a higher market share in the global rheumatoid arthritis testing market owing to the ease of use and quick results.

Key Insights

• Prevalence of Rheumatoid Arthritis for Key Countries


• Reimbursement Scenario for Key Countries


• Key Mergers and Acquisitions


• New Product Launches


• Overview of Technological Advancements in Rheumatoid Arthritis Testing


• Pricing Analysis


• Porter’s Five Forces Analysis

Regional Analysis

The global rheumatoid arthritis testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The rheumatoid arthritis testing market is anticipated to expand in North America during the forecast years owing to the new product launches, technological advancements, and increasing number of patients with rheumatoid arthritis.

To gain extensive insights into the market, Request for Customization

The Centers for Disease Control and Prevention (CDC) projected that by 2040, 78.4 million people worldwide would be diagnosed with arthritis compared with the 54.4 million in 2013-2015 and approximately 34.6 million adults will be reported with arthritis attributed activity limitations, which is expected to drive the rheumatoid arthritis testing market in North America. In Europe, the high prevalence of rheumatoid arthritis and the adoption of technologically advanced tests are projected to augment the rheumatoid arthritis testing market by the end of 2026. In the Asia Pacific and Latin America, the evolving healthcare infrastructure and increasing awareness regarding rheumatoid arthritis are anticipated to fuel the rheumatoid arthritis testing market growth during the forecast period. Additionally, rheumatoid arthritis testing market in the Middle East and Africa is in the nascent stage; however, unmet needs for rheumatoid arthritis treatment is expected to drive the market growth in this region.

Segmentation

Rheumatoid Arthritis Testing Industry Developments

• In January 2019, Microdrop LLC (imaware), announced the launch of their at-home rheumatoid arthritis screening test


• In September 2018, Exagen Inc. announced the launch of the first validated test for the detection of anticarbamylated protein antibodies which is found to be significantly elevated in patients of rheumatoid arthritis